Transition report pursuant to Rule 13a-10 or 15d-10

Transition Period Comparative Data (Details)

v3.5.0.2
Transition Period Comparative Data (Details) - USD ($)
3 Months Ended 9 Months Ended 11 Months Ended 12 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Mar. 31, 2016
Mar. 31, 2015
Jun. 30, 2016
Mar. 31, 2016
Jun. 30, 2015
Expenses              
Research and development $ 709,314 $ 228,125   $ 244,635 $ 1,758,701 $ 1,222,194 $ 470,987
General and administrative 968,734 625,917   339,214 2,935,299 2,647,800 920,031
Total expense 1,678,048 854,042   583,849 4,694,000 3,869,994 1,391,018
Other income (expenses)              
Grant income 20,500 29,999   137,500 254,834 264,333 167,499
Interest income 186 175   1,339 1,328 175
Change in fair value of warrant derivative liability (860,275) 1,571   (968,840) (106,994) 1,571
Total other income (expenses) (839,589) 31,745   137,500 (712,167) 159,167 169,245
Net loss for the period $ (2,517,637) $ (822,297) $ (2,888,530) $ (446,349) $ (5,406,167) $ (3,710,827) $ (1,221,773)
Loss per share - basic and diluted (in dollars per share) $ (0.17) $ (0.11)   $ (0.08) $ (0.40) $ (0.32) $ (0.20)
Weighted average number of shares outstanding - basic and diluted (in shares) 15,111,088 7,823,683   5,493,200 13,349,482 11,702,313 6,240,780
Cash flow Data:              
Net cash used in operating activities $ (1,100,342) $ (576,492)   $ (433,065) $ (3,312,969) $ (2,789,118) $ (980,044)
Net cash used in investing activities (47,215) (23,378)   (99,197) (203,667) (179,830) (111,727)
Net cash provided by financing activities 2,572,896 4,241,627   1,220,001 3,342,584 5,011,314 4,931,627
Net increase in cash for the period $ 1,425,339 $ 3,641,757   $ 687,739 $ (174,052) $ 2,042,366 $ 3,839,856